



PRIOR AUTHORIZATION POLICY

- POLICY:** Gaucher Disease – Substrate Reduction Therapy – Miglustat Prior Authorization Policy
- Zavesca® (miglustat capsules – Actelion, generic)

REVIEW DATE: 05/29/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Miglustat capsules (Zavesca, generic), a glucosylceramide synthase inhibitor, is indicated as monotherapy for the treatment of mild to moderate **Gaucher disease type 1** in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to allergy, hypersensitivity, or poor venous access).¹

Disease Overview

Gaucher disease is caused by a deficiency in the lysosomal enzyme β -glucocerebrosidase.² This enzyme is responsible for the breakdown of glucosylceramide into glucose and ceramide. In Gaucher disease, deficiency of the enzyme β -glucocerebrosidase results in the accumulation of glucosylceramide substrate in lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells." Miglustat is a specific inhibitor of the enzyme glycosylceramide synthase, which is responsible for producing the substrate glucosylceramide.¹ By functioning as a substrate reduction therapy, miglustat allows the residual activity of the deficient glucocerebrosidase enzyme to be more effective.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of miglustat capsules (Zavesca, generic). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with miglustat capsules as well as the monitoring required for adverse events and long-term efficacy, approval requires miglustat capsules to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Zavesca® (miglustat capsules (Actelion, generic)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

- 1. Gaucher Disease Type 1.** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A)** The diagnosis is established by ONE of the following (i or ii):
 - i.** Demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts; OR
 - ii.** Molecular genetic test documenting biallelic pathogenic glucocerebrosidase (*GBA*) gene variants; AND
 - B)** The medication is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or a physician who specializes in the treatment of Gaucher disease or related disorders.

CONDITIONS NOT COVERED

- **Zavesca® (miglustat capsules (Actelion, generic)**

is(are) considered experimental, investigational or unproven for ANY other use(s)

REFERENCES

1. Zavesca® capsules [prescribing information]. South San Francisco, CA: Actelion; August 2022.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	05/10/2023
Annual Revision	Gaucher Disease Type 1: Confirmation of a genetic mutation in the glucocerebrosidase gene was rephrased to more specifically state,	05/29/2024

	"genetic test documenting biallelic pathogenic glucocerebrosidase (<i>GBA</i>) gene variants".	
--	--	--

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.